Voriconazole Serum Concentrations in Obese and Overweight Immunocompromised Patients: A Retrospective Review

Study Objective To evaluate the relationship between voriconazole dose and corresponding serum concentrations in obese and overweight immunocompromised patients. Design Retrospective medical record review. Setting National Cancer Institute–designated comprehensive cancer center. Patients A total of 92 patients with hematologic malignancies and/or hematopoietic stem cell transplants who received voriconazole and had reported steady‐state serum concentrations (peak, random, or trough) during 2005–2010; 124 serum concentrations were available for analysis. Measurements and Main Results Data on patient demographics, voriconazole concentrations, and other clinical and safety data were collected. Patients were stratified based on body mass index (BMI). Patients with higher BMIs tended to have significantly higher median random voriconazole concentrations with intravenous administration (6.4 mg/L for BMI ≥ 25 kg/m2 vs 2.8 mg/L for BMI